kynurenic acid has been researched along with ro 61-8048 in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cesura, AM; Huguenin, P; Kettler, R; Röver, S; Szente, A | 1 |
| Obrenovitch, TP; Urenjak, J | 2 |
| Ballerini, C; Chiarugi, A; Cozzi, A; Massacesi, L; Moroni, F | 1 |
| Carpenedo, R; Meli, E; Moroni, F; Pellegrini-Giampietro, DE; Peruginelli, F | 1 |
| Carpendo, R; Cipriani, G; Cozzi, A; Izzo, E; Moroni, F; Veneroni, O | 1 |
| Bédard, PJ; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R | 1 |
| Bédard, PJ; Di Paolo, T; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R | 1 |
| Ball, HJ; Hunt, NH; Mellor, AL; Miu, J | 1 |
| Adame, A; Andrews-Zwilling, Y; Flik, G; Giorgini, F; Guidetti, P; Hsieh, EW; Huang, SY; Huang, Y; Laue, G; Lee, J; Louie, JY; Masliah, E; Moussaoui, S; Muchowski, JM; Muchowski, PJ; Notarangelo, FM; Patrick, C; Rassoulpour, A; Sathyasaikumar, KV; Scearce-Levie, K; Schwarcz, R; Truong, J; Wu, HQ; Wu, T; Zwilling, D | 1 |
| Barnes, C; Bergman, J; Ferré, S; Fratta, W; Goldberg, SR; Justinova, Z; Kangas, BD; Mascia, P; Panlilio, LV; Parashos, A; Pistis, M; Redhi, GH; Scherma, M; Schwarcz, R; Secci, ME; Solinas, M; Tanda, G; Wu, HQ; Zara, T | 1 |
| Auber, A; Goldberg, SR; Justinova, Z; Panlilio, LV; Redhi, GH; Schindler, CW; Schwarcz, R; Secci, ME; Thorndike, EB | 1 |
| Beggiato, S; Borelli, AC; Bradberry, CW; Ferraro, L; Ferré, S; Goldberg, SR; Justinova, Z; Mascia, P; Melis, M; Panlilio, LV; Pistis, M; Sagheddu, C; Schindler, CW; Schwarcz, R; Secci, ME; Tanda, G; Tomasini, MC | 1 |
13 other study(ies) available for kynurenic acid and ro 61-8048
| Article | Year |
|---|---|
Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase.
Topics: Animals; Brain; Enzyme Inhibitors; Extracellular Space; Gerbillinae; Kidney; Kinetics; Kynurenic Acid; Kynurenine 3-Monooxygenase; Liver; Mitochondria; Mixed Function Oxygenases; Molecular Structure; Neuroprotective Agents; Rats; Structure-Activity Relationship; Sulfonamides; Thiazoles | 1997 |
In vivo assessment of kynurenate neuroprotective potency and quinolinate excitotoxicity.
Topics: Animals; Enzyme Inhibitors; Frontal Lobe; Kynurenic Acid; Male; Neuroprotective Agents; Quinolinic Acid; Rats; Sulfonamides; Thiazoles | 2000 |
Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced depolarisation in the striatum.
Topics: Administration, Oral; Animals; Cerebral Cortex; Corpus Striatum; Electroencephalography; Enzyme Inhibitors; Extracellular Space; Injections, Intraperitoneal; Kynurenic Acid; Kynurenine 3-Monooxygenase; Male; Membrane Potentials; Microdialysis; Mixed Function Oxygenases; N-Methylaspartate; Neuroprotective Agents; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate; Sulfonamides; Thiazoles | 2000 |
Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis.
Topics: Animals; Astrocytes; Brain; Cytoplasmic Granules; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Female; Immunohistochemistry; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Mixed Function Oxygenases; Multiple Sclerosis; Neurons; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Rats; Rats, Wistar; Spinal Cord; Sulfonamides; Thiazoles | 2001 |
Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures.
Topics: Alanine; Animals; Brain Ischemia; Cell Death; Cell Hypoxia; Culture Media, Conditioned; Enzyme Inhibitors; Glucose; Hippocampus; In Vitro Techniques; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Mixed Function Oxygenases; Neurons; Neuroprotective Agents; Pyramidal Cells; Quinolinic Acid; Rats; Sulfonamides; Thiazoles | 2002 |
Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus.
Topics: Animals; Avoidance Learning; Basal Ganglia; Behavior, Animal; Brain Chemistry; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Glutamic Acid; Kynurenic Acid; Kynurenine 3-Monooxygenase; Male; Microdialysis; Mixed Function Oxygenases; omega-Conotoxin GVIA; Potassium Chloride; Rats; Rats, Wistar; Statistics, Nonparametric; Sulfonamides; Thiazoles; Time Factors | 2005 |
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Kynurenic Acid; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Mixed Function Oxygenases; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors | 2005 |
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors | 2008 |
Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria.
Topics: Animals; Brain; Enzyme Inhibitors; Female; Gas Chromatography-Mass Spectrometry; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Malaria, Cerebral; Metabolic Networks and Pathways; Mice; Mice, Inbred C57BL; Picolinic Acids; Quinolinic Acid; RNA, Messenger; Sulfonamides; Thiazoles; Tryptophan Oxygenase | 2009 |
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.
Topics: Administration, Oral; Alzheimer Disease; Animals; Brain Chemistry; Disease Models, Animal; Female; Humans; Huntington Disease; Kynurenic Acid; Kynurenine 3-Monooxygenase; Male; Mice; Mice, Transgenic; Sulfonamides; Thiazoles | 2011 |
Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid.
Topics: Analgesics; Animals; Benzoxazines; Brain; Cannabinoid Receptor Agonists; Conditioning, Operant; Cues; Discrimination, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug-Seeking Behavior; Kynurenic Acid; Male; Memory, Short-Term; Morpholines; Naphthalenes; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Reinforcement, Psychology; Saimiri; Secondary Prevention; Self Administration; Substance-Related Disorders; Sulfonamides; Thiazoles; Time Factors; Wakefulness | 2013 |
Attenuating Nicotine Reinforcement and Relapse by Enhancing Endogenous Brain Levels of Kynurenic Acid in Rats and Squirrel Monkeys.
Topics: Animals; Cocaine; Dopamine; Isoxazoles; Kynurenic Acid; Male; Nicotine; Nucleus Accumbens; Phenylurea Compounds; Rats; Recurrence; Reinforcement, Psychology; Saimiri; Secondary Prevention; Self Administration; Sulfonamides; Thiazoles | 2017 |
Astrocytic Mechanisms Involving Kynurenic Acid Control Δ
Topics: Action Potentials; alpha7 Nicotinic Acetylcholine Receptor; Animals; Astrocytes; Brain; Cells, Cultured; Dronabinol; Glutamic Acid; Kynurenic Acid; Male; Nucleus Accumbens; Prefrontal Cortex; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Reward; Rimonabant; RNA, Messenger; Sulfonamides; Thiazoles; Ventral Tegmental Area | 2019 |